| Authors: |
Sarntivijai S; ELIXIR Hub, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK., Blomberg N; ELIXIR Hub, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK., Lauer KB; ELIXIR Hub, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK., Briggs K; Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK., Steger-Hartmann T; Bayer AG, Research & Development, Pharmaceuticals, Investigational Toxicology, 13342 Berlin, Germany., van der Lei J; Department of Medical Informatics, Erasmus University Rotterdam, EUR - Erasmus Medical Center (MC), Rotterdam, The Netherlands., Sauer JM; Predictive Safety Testing Consortium, Critical Path Institute, Tucson, Arizona, 85718, USA., Liwski R; Predictive Safety Testing Consortium, Critical Path Institute, Tucson, Arizona, 85718, USA., Mourby M; Centre for Health, Law and Emerging Technologies (HeLEX), Faculty of Law, University of Oxford, Oxford, OX2 7DD, UK., Camprubi M; Synapse Research Management Partners S.L., C. Diputació 237, Àtic 3a, 08007, Barcelona, Spain. |
